StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
20
Publishing Date
2023 - 10 - 02
1
2023 - 09 - 28
1
2023 - 08 - 15
1
2023 - 06 - 27
1
2023 - 04 - 26
1
2023 - 03 - 28
1
2023 - 03 - 27
1
2023 - 02 - 22
1
2022 - 12 - 16
1
2022 - 09 - 06
1
2022 - 03 - 16
1
2021 - 12 - 03
1
2021 - 11 - 18
1
2021 - 09 - 29
1
2021 - 08 - 02
1
2021 - 05 - 21
1
2021 - 05 - 03
1
2021 - 02 - 11
1
2021 - 02 - 08
2
Sector
Health technology
20
Tags
Aav9
1
Acquisition
2
Acquisition corp
2
America
2
Application
1
Approval
7
Asia
1
Award
1
Biopharma
2
Biotech
2
Biotechnology
2
Care
2
Ceo
1
Ces
1
Chmp
2
Clinical-trials-phase-iii
1
Collaboration
1
Company announcement
1
Conference
18
Directors and officers
1
Disease
20
Earnings
7
Europe
3
Ev
1
Events
10
Expected
1
Extension
1
Fda
4
Fda acceptance
1
Financial
12
Financial results
9
Gene therapies
2
Gene therapy
3
Genetic
1
Germany
1
Global
1
Grant
1
Granted
1
Growth
1
Health
3
Iot
2
J.p. morgan healthcare conference
2
Lancet
1
Market
1
Mergers-and-acquisitions
1
N/a
58
Opfolda
1
People
3
Pharm-country
5
Phase 3
2
Pos
2
Positive
6
Presentation
9
Regulatory
2
Research
2
Results
25
Technology
2
Therapeutics
56
Therapy
7
Treatment
7
Entities
Amicus therapeutics, inc.
20
Eli lilly and company
1
Johnson & johnson
1
Novartis ag
1
Sanofi
1
Takeda pharmaceutical company limited
1
Symbols
ABBV
65
ABOS
14
ABT
67
ACIU
21
ALDX
17
ALPMF
16
ALPMY
16
AMGN
26
ANVS
29
ATHA
24
ATHE
14
AVXL
24
AZN
34
AZNCF
23
BBIO
15
BDX
24
BEAM
15
BHC
20
BIIB
74
BIO
16
BIVI
32
BMY
22
BSX
16
CGTX
22
CNTG
23
CYTH
19
DHR
18
DNLI
15
FDMT
14
FNCTF
21
FOLD
20
GANX
20
GBT
33
GILD
20
GLAXF
24
GSK
39
HZNP
23
INCY
16
INMB
16
IONS
14
JNJ
107
LLY
89
MDT
30
MESO
24
NVO
18
NVS
76
NVSEF
61
PFE
28
PHG
15
REGN
16
RGLS
23
SAVA
26
SNY
179
SNYNF
130
TAK
33
TEVJF
36
TMO
47
VRTX
17
VTRS
16
ZVSA
18
Exchanges
Nasdaq
20
Nyse
1
Crawled Date
2023 - 10 - 02
1
2023 - 09 - 28
1
2023 - 08 - 15
1
2023 - 06 - 27
1
2023 - 04 - 26
1
2023 - 03 - 28
1
2023 - 03 - 27
1
2023 - 02 - 22
1
2022 - 12 - 16
1
2022 - 09 - 06
1
2022 - 03 - 16
1
2021 - 12 - 03
1
2021 - 11 - 18
1
2021 - 09 - 29
1
2021 - 08 - 02
1
2021 - 05 - 21
1
2021 - 05 - 03
1
2021 - 02 - 11
1
2021 - 02 - 08
2
Crawled Time
01:00
2
11:00
4
12:00
3
12:30
1
13:00
1
13:20
1
15:00
2
18:00
1
20:00
2
21:03
1
22:00
1
23:00
1
Source
www.biospace.com
7
www.globenewswire.com
11
www.prnewswire.com
2
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Disease
symbols :
Fold
save search
WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease
Published:
2023-10-02
(Crawled : 01:00)
- prnewswire.com
FOLD
F
|
$10.7
-1.11%
-1.12%
3.2M
|
Health Technology
|
-11.02%
|
O:
-0.66%
H:
0.66%
C:
-8.69%
fda
disease
approval
treatment
therapeutics
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
Published:
2023-09-28
(Crawled : 15:00)
- globenewswire.com
FOLD
F
|
$10.7
-1.11%
-1.12%
3.2M
|
Health Technology
|
-15.99%
|
O:
-1.32%
H:
1.73%
C:
-6.69%
fda
disease
approval
treatment
therapeutics
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
Published:
2023-08-15
(Crawled : 11:00)
- globenewswire.com
FOLD
F
|
$10.7
-1.11%
-1.12%
3.2M
|
Health Technology
|
-18.59%
|
O:
0.3%
H:
0.0%
C:
-2.55%
disease
approval
therapeutics
therapy
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
Published:
2023-06-27
(Crawled : 11:00)
- globenewswire.com
FOLD
F
|
$10.7
-1.11%
-1.12%
3.2M
|
Health Technology
|
-10.36%
|
O:
0.41%
H:
1.57%
C:
0.41%
disease
approval
therapeutics
therapy
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
Published:
2023-04-26
(Crawled : 18:00)
- globenewswire.com
FOLD
F
|
$10.7
-1.11%
-1.12%
3.2M
|
Health Technology
|
-6.32%
|
O:
-0.61%
H:
3.14%
C:
0.7%
opfolda
disease
chmp
positive
therapeutics
WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
Published:
2023-03-28
(Crawled : 15:00)
- biospace.com/
FOLD
F
|
$10.7
-1.11%
-1.12%
3.2M
|
Health Technology
|
-2.35%
|
O:
0.9%
H:
2.68%
C:
0.27%
disease
approval
therapeutics
Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
Published:
2023-03-27
(Crawled : 13:00)
- biospace.com/
FOLD
F
|
$10.7
-1.11%
-1.12%
3.2M
|
Health Technology
|
-2.61%
|
O:
0.9%
H:
0.27%
C:
-1.16%
disease
approval
therapeutics
Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023
Published:
2023-02-22
(Crawled : 22:00)
- globenewswire.com
FOLD
F
|
$10.7
-1.11%
-1.12%
3.2M
|
Health Technology
|
-17.15%
|
O:
0.23%
H:
0.11%
C:
-0.38%
disease
extension
therapeutics
positive
study
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
Published:
2022-12-16
(Crawled : 13:20)
- globenewswire.com
FOLD
F
|
$10.7
-1.11%
-1.12%
3.2M
|
Health Technology
|
-10.5%
|
O:
-0.66%
H:
4.08%
C:
1.83%
disease
chmp
therapeutics
positive
Lysosomal Disease Treatment Market to Reach $14.1 Billion, Globally, by 2031 at 6.4% CAGR: Allied Market Research
Published:
2022-09-06
(Crawled : 01:00)
- prnewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
18.0%
|
O:
-2.93%
H:
10.14%
C:
3.79%
TAK
|
News
|
$13.38
0.15%
0.9%
1.7M
|
Health Technology
|
-1.62%
|
O:
-0.44%
H:
0.0%
C:
-1.11%
NVS
|
News
|
$97.28
2.27%
0.31%
3.7M
|
Health Technology
|
18.91%
|
O:
1.22%
H:
0.46%
C:
-1.12%
JNJ
|
News
|
$149.56
0.3%
0.0%
9.1M
|
Health Technology
|
-10.06%
|
O:
-1.1%
H:
0.0%
C:
0.0%
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
142.7%
|
O:
0.54%
H:
3.26%
C:
1.28%
SNY
|
News
|
$47.69
1.15%
1.13%
1.7M
|
Health Technology
|
14.6%
|
O:
-1.35%
H:
0.0%
C:
0.0%
FOLD
F
|
$10.7
-1.11%
-1.12%
3.2M
|
Health Technology
|
-5.58%
|
O:
0.0%
H:
0.17%
C:
-2.36%
treatment
research
disease
market
Amicus Therapeutics Announces Positive Long-Term Data from Phase 1/2 Study of AT-GAA in Pompe Disease at the 2022 MDA Clinical & Scientific Conference
Published:
2022-03-16
(Crawled : 11:00)
- globenewswire.com
FOLD
F
|
$10.7
-1.11%
-1.12%
3.2M
|
Health Technology
|
20.89%
|
O:
1.34%
H:
4.74%
C:
4.74%
pos
conference
therapeutics
disease
phase 1
positive
European Medicines Agency Validates Amicus Therapeutics Marketing Authorization Applications for AT-GAA for the Treatment of Pompe Disease
Published:
2021-12-03
(Crawled : 12:30)
- globenewswire.com
FOLD
F
|
$10.7
-1.11%
-1.12%
3.2M
|
Health Technology
|
0.65%
|
O:
2.98%
H:
0.0%
C:
0.0%
treatment
europe
application
therapeutics
disease
The Lancet Neurology Publishes Pivotal Phase 3 PROPEL Study Results of AT-GAA in Late-Onset Pompe Disease
Published:
2021-11-18
(Crawled : 23:00)
- biospace.com/
FOLD
F
|
$10.7
-1.11%
-1.12%
3.2M
|
Health Technology
|
-6.64%
|
O:
0.43%
H:
1.37%
C:
-1.89%
disease
results
phase 3
lancet
U.S. FDA Accepts Filings for Amicus’ AT-GAA for the Treatment of Pompe Disease
Published:
2021-09-29
(Crawled : 11:00)
- biospace.com/
FOLD
F
|
$10.7
-1.11%
-1.12%
3.2M
|
Health Technology
|
6.29%
|
O:
10.5%
H:
0.0%
C:
-14.13%
disease
treatment
fda
fda acceptance
Amicus Therapeutics Announces European Commission Approval of Galafold® (migalastat) for Adolescents with Fabry Disease
Published:
2021-08-02
(Crawled : 12:00)
- biospace.com/
FOLD
F
|
$10.7
-1.11%
-1.12%
3.2M
|
Health Technology
|
16.78%
|
O:
0.16%
H:
1.72%
C:
1.29%
disease
europe
approval
Amicus Therapeutics Announces Upcoming Presentations at the 16th International Congress on Neuromuscular Diseases
Published:
2021-05-21
(Crawled : 12:00)
- biospace.com/
FOLD
F
|
$10.7
-1.11%
-1.12%
3.2M
|
Health Technology
|
18.25%
|
O:
1.75%
H:
0.0%
C:
-3.76%
presentation
disease
Amicus Therapeutics Announces Successful Pre-BLA Meeting with U.S. FDA for AT-GAA for the Treatment of Pompe Disease
Published:
2021-05-03
(Crawled : 12:00)
- biospace.com/
FOLD
F
|
$10.7
-1.11%
-1.12%
3.2M
|
Health Technology
|
9.96%
|
O:
3.76%
H:
2.94%
C:
0.69%
disease
treatment
fda
Amicus’ AT-GAA Shows Clinically Meaningful & Significant Improvements in Both Musculoskeletal and Respiratory Measures in Late-Onset Pompe Disease Compared to Standard of Care in Pivotal Phase 3 PROPEL Study
Published:
2021-02-11
(Crawled : 21:03)
- globenewswire.com
FOLD
F
|
$10.7
-1.11%
-1.12%
3.2M
|
Health Technology
|
-42.23%
|
O:
-24.7%
H:
1.74%
C:
-10.88%
disease
respiratory
phase 3
Amicus Therapeutics Presents Positive Preclinical Fabry Disease Gene Therapy Data at the 17th Annual WORLDSymposium™ 2021
Published:
2021-02-08
(Crawled : 20:00)
- globenewswire.com
FOLD
F
|
$10.7
-1.11%
-1.12%
3.2M
|
Health Technology
|
-45.52%
|
O:
0.76%
H:
0.7%
C:
-3.95%
gene therapy
positive
therapy
disease
gene therapies
preclinical
pre-clinical
Amicus Therapeutics Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene Therapy at the 17th Annual WORLDSymposium™ 2021
Published:
2021-02-08
(Crawled : 20:00)
- globenewswire.com
FOLD
F
|
$10.7
-1.11%
-1.12%
3.2M
|
Health Technology
|
-45.52%
|
O:
0.76%
H:
0.7%
C:
-3.95%
gene therapy
positive
therapy
disease
gene therapies
Gainers vs Losers
78%
22%
Top 10 Gainers
MTTR
|
News
M
|
$4.6
164.37%
62.17%
28M
|
AGBA
|
$2.94
135.2%
57.48%
66M
|
Finance
EDBL
|
News
|
$6.46
71.81%
41.8%
2M
|
MTC
|
$2.25
44.23%
30.67%
6M
|
Technology Services
OPRT
|
News
|
$3.175
41.11%
29.13%
12M
|
Finance
SHIM
|
$3.05
35.56%
26.23%
1.1M
|
HKIT
|
$1.345
31.86%
24.16%
390K
|
Technology Services
ABVC
|
$1.36
30.77%
23.53%
7.4M
|
Wholesale Trade
OST
|
$0.512
28.0%
21.88%
290K
|
POET
|
$1.59
27.2%
21.38%
4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.